Checking in on RAPT Therapeutics Inc. (RAPT) after recent insiders movement

0
53

RAPT Therapeutics Inc.’s recently made public that its Chief Medical Officer HO WILLIAM unloaded Company’s shares for reported $0.13 million on Jan 19. In the deal valued at $25.56 per share,5,000 shares were sold. As a result of this transaction, HO WILLIAM now holds 35,072 shares worth roughly $ 1.0 million.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Then, Brockstedt Dirk G. sold 742 shares, generating $16,299 in total proceeds. Upon selling the shares at $21.97, the Chief Scientific Officer now owns 19,070 shares.

Before that, HO WILLIAM sold 5,000 shares. RAPT Therapeutics Inc. shares valued at $90,150 were divested by the Chief Medical Officer at a price of $18.03 per share. As a result of the transaction, HO WILLIAM now holds 37,650 shares, worth roughly $1.07 million.

Guggenheim initiated its RAPT Therapeutics Inc. [RAPT] rating to a Buy in a research note published on Tuesday, January 04, 2023; the price target was $55. PT values the company’s stock at a premium of 48.13 to its Tuesday closing price. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. CapitalOne began covering RAPT with “an Overweight” recommendation on September 21, 2022.

Price Performance Review of RAPT

On Tuesday, RAPT Therapeutics Inc. [NASDAQ:RAPT] saw its stock jump 0.88% to $28.53. On the same session, the stock had its day’s lowest price of $28.10, but rose to a high of $30.66. Over the last five days, the stock has gained 6.69%. RAPT Therapeutics Inc. shares have risen nearly 44.09% since the year began. Nevertheless, the stocks have risen 35.86% over the past one year. While a 52-week high of $32.45 was reached on 01/24/23, a 52-week low of $9.85 was recorded on 01/03/23. SMA at 50 days reached $20.44, while 200 days put it at $20.43. A total of 0.55 million shares were traded, compared to the trading of 0.38 million shares in the previous session.

Levels Of Support And Resistance For RAPT Stock

The 24-hour chart illustrates a support level at 27.53, which if violated will result in even more drops to 26.54. On the upside, there is a resistance level at 30.09. A further resistance level may holdings at 31.66. The Relative Strength Index (RSI) on the 14-day chart is 72.51, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.06, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.59%. Stochastics %K at 92.78% indicates the stock is a selling.

How much short interest is there in RAPT Therapeutics Inc.?

A steep rise in short interest was recorded in RAPT Therapeutics Inc. stocks on Oct 13, 2022, growing by 0.23 million shares to a total of 2.88 million shares. Yahoo Finance data shows the prior-month short interest on Sep 14, 2022 was 2.65 million shares. There was a rise of 7.99%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 13.15% of the overall stock float, the days-to-cover ratio (short ratio) rose to 8.4.

RAPT Therapeutics Inc. [RAPT] – Who Are The Largest Shareholders?

In filings from T. Rowe Price Associates, Inc., it is revealed that the company now owns 3,079,742 shares, or roughly 9.07% of the outstanding RAPT shares. In other words, the investor’s shares have fallen by -1,254,941 from its previous 13-F filing of 4334683.0. Additionally, FIAM LLC decreased -14.77% of its stake after which the total value it holdings stand at $50,035,135, while Perceptive Advisors LLC reduced -10.48% of its stake to hold $33.92 million in the firm. Over the last quarter, BlackRock Fund Advisors sold -8,466 shares of RAPT Therapeutics Inc., while SSgA Funds Management, Inc. sold 783,026 shares. At present, T. Rowe Price Investment Manageme is holding 1,244,671 shares valued at $24.64 million. The Vanguard Group, Inc. owned 1,229,252 shares of the company at the time of its most recent 13F filing, worth $24.34 million.

According to FactSet, RAPT Therapeutics Inc.’s share price will average $46.20 in the next year, based on opinions of analysts polled by the firm. This is up nearly 69.73 percent from its previous closing price of $28.28. Analysts expect RAPT Therapeutics Inc. stock to reach the higher price of $61.00, while the lowest price estimate is $27.00. However, 10 analysts have rated RAPT stock as a Buy in their predictions for 2023. The most recent change occurred on December 09, 2021 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $61 price target.

LEAVE A REPLY

Please enter your comment!
Please enter your name here